Brief: Gamida Cell Completes Rolling Biologics License Application Submission To The FDA For Omidubicel
02/06/2022 12:12
June 2 (Reuters) - Gamida Cell Ltd GMDA.O :
* GAMIDA CELL COMPLETES ROLLING BIOLOGICS LICENSE
APPLICATION
SUBMISSION TO THE FDA FOR OMIDUBICEL
Source text for Eikon: ID:nBw7XMLsva
Further company coverage: GMDA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Gamida Cell
See all newsBrief: Gamida Cell Appoints Joe Wiley As CEO
Brief: Gamida Cell Says District Court Of Beersheba, Israel Entered Judgment In Restructuring Proceeding
Israeli ADRs up on hopes of de-escalation in Israel-Iran tensions
Brief: Aquestive Therapeutics Strengthens Board Of Directors With Experienced Biotech Executive
Brief: Gamida Cell Ltd Says Received Notice From Nasdaq Notifying Co That It Determined Co’S Ordinary Shares Will Be Delisted From Nasdaq